Physician profile
Michael Crawley
NPI 1518928027
$2,268.14
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $426 · 2021: $735 · 2022: $601 · 2023: $77.53 · 2024: $67.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $384.04 | 2019-2022 | |
| Glaxosmithkline, LLC. | $325.01 | 2020-2023 | Trelegy Ellipta |
| Pfizer INC. | $261.44 | 2019-2022 | |
| Abbott Laboratories | $261.14 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $256.05 | 2019-2022 | |
| Abbvie INC. | $230.74 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.81 | 2019-2022 | |
| Astellas Pharma US INC | $70.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $64.95 | 2021-2022 | |
| Allergan, INC. | $42.72 | 2020 | |
| Merck Sharp & Dohme LLC | $41.83 | 2019-2020 | |
| Lilly USA, LLC | $39.13 | 2020-2021 | |
| Genentech USA, INC. | $36.67 | 2020-2021 | |
| Novo Nordisk INC | $31.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.25 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.71 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $14.35 | 2022 | |
| Eisai INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Crawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.